← board
MDCX
distress 8/10 · high distress / dilution risk$0.37-1%today-89% from 52w high
Revenue
pre-revenue
Liquidity
$6M
Runway
0.2 yrs
Shares 1y
+218%
Price & events
-72.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
-8.5%
1W
-18.4%
1M
+11.9%
3M
-72.9%
6M
-87.8%
1Y
—
2Y
—
5Y
-86.0%
All
Overview
- Market Cap
- $21.05M
- Volume
- 50.87K
- 52 Week Range
- $0.28 – $3.25
- Total Shares
- 56.66M
- Float Shares
- 50.34M
- Short %
- 1.95%
- % Held by Insiders
- 12.48%
- % Held by Institutions
- 4.08%
- RVOL
- 0.03x
- Beta
- -0.65
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2025-09-17partnershipIssued $8M debenture to YA II PN, Ltd.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 56,658,164 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-20D. Boral CapitalBuy
- 2026-03-19D. Boral CapitalBuy
- 2026-03-09D. Boral CapitalBuy
- 2025-12-15D. Boral CapitalBuy
- 2025-11-17D. Boral CapitalBuy
- 2025-11-13D. Boral CapitalBuy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.